The Serum Institute of India is set to increase its production capacity, anticipating a two-fold rise in the sales of critical vaccines, including those for malaria and cervical cancer, over the next five years.
As one of the world’s leading vaccine manufacturer, the company currently has the capability to produce three billion doses annually across various types of vaccines, although it currently sells about 1.5 billion doses each year.
The demand for the malaria vaccine is gradually increasing, with several African nations gearing up for its distribution. Serum dispatched the initial batch of the ‘R21/Matrix-M’ malaria vaccine to Africa in May, marking it as the second malaria vaccine authorized for children globally. The company estimates it will take approximately two years for demand to match supply.
As reported by mint, Serum will provide millions of doses of its HPV vaccine, Cervavac, to the Indian government at a discounted rate under the universal immunization program. The institute is also developing vaccines to address four strains of the dengue virus as well as flu viruses that can lead to outbreaks in certain regions.
